Nature Communications (Nov 2018)
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer
- Gordon C. Jayson,
- Cong Zhou,
- Alison Backen,
- Laura Horsley,
- Kalena Marti-Marti,
- Danielle Shaw,
- Nerissa Mescallado,
- Andrew Clamp,
- Mark P. Saunders,
- Juan W. Valle,
- Saifee Mullamitha,
- Mike Braun,
- Jurjees Hasan,
- Delyth McEntee,
- Kathryn Simpson,
- Ross A. Little,
- Yvonne Watson,
- Susan Cheung,
- Caleb Roberts,
- Linda Ashcroft,
- Prakash Manoharan,
- Stefan J. Scherer,
- Olivia del Puerto,
- Alan Jackson,
- James P. B. O’Connor,
- Geoff J. M. Parker,
- Caroline Dive
Affiliations
- Gordon C. Jayson
- The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester
- Cong Zhou
- Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester
- Alison Backen
- Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute & Manchester Centre for Cancer Biomarker Sciences
- Laura Horsley
- The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester
- Kalena Marti-Marti
- The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester
- Danielle Shaw
- Clatterbridge Cancer Centre
- Nerissa Mescallado
- The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester
- Andrew Clamp
- Manchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust
- Mark P. Saunders
- Manchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust
- Juan W. Valle
- The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester
- Saifee Mullamitha
- Manchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust
- Mike Braun
- Manchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust
- Jurjees Hasan
- Manchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust
- Delyth McEntee
- Manchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust
- Kathryn Simpson
- Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute & Manchester Centre for Cancer Biomarker Sciences
- Ross A. Little
- Imaging Sciences, University of Manchester
- Yvonne Watson
- Imaging Sciences, University of Manchester
- Susan Cheung
- Imaging Sciences, University of Manchester
- Caleb Roberts
- Imaging Sciences, University of Manchester
- Linda Ashcroft
- Manchester Academic Health Science Centre, Trials Co-ordination Unit, The Christie NHS Foundation Trust
- Prakash Manoharan
- The Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester
- Stefan J. Scherer
- Novartis Pharmaceuticals Corporation
- Olivia del Puerto
- Del Puerto Limited
- Alan Jackson
- Imaging Sciences, University of Manchester
- James P. B. O’Connor
- Division of Cancer Sciences, Manchester Cancer Research Centre, University of Manchester
- Geoff J. M. Parker
- Imaging Sciences, University of Manchester
- Caroline Dive
- Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute & Manchester Centre for Cancer Biomarker Sciences
- DOI
- https://doi.org/10.1038/s41467-018-07174-1
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 14
Abstract
Identification of response biomarkers is a key step towards the development of personalised care. Here, Jayson et al. identify plasma Tie2 as a biomarker for the response of the tumor vasculature to anti-angiogenics in patients with metastatic colorectal cancer, suggesting that monitoring Tie2 levels may help guide therapy in the clinics.
